retatrutide phase 2 trial type 2 diabetes 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Phase 2: Type 2

The Research History in One Sentence Ipamorelin has established receptor pharmacology and limited human research, but the controlled proof of concept study did not demonstrate significant differences in its main efficacy analyses and did not lead to an identified UK authorisation

The black box warning notes that GLP-1s such as Mounjaro are contraindicated for individuals with a history or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2

For instance, Mansur et al

All of these joys combined make losing weight a truly gratifying experience

An ampoule opener may be required for safe opening and handling